Comparing imaging techniques to diagnose lung cancer – looking for advisors
Are you interested in helping research to improve accuracy in earlier diagnosis of lung cancer from different imaging types?
We’re looking for people who’ve had imaging for suspected lung cancer whether or not they’ve gone on to be diagnosed, as well as those who’ve been diagnosed and treated.
What is it for?
A group led by the University of Oxford is planning a research study exploring whether a CT scan can diagnose lung cancer earlier than the chest x-ray currently performed when lung cancer is suspected. As part of this research, the team is inviting people to join a patient and public involvement (PPI) advisory group.
What is the purpose of the PPI advisory group?
The group’s purpose is to ensure the experiences and views of those referred for chest imaging for suspected lung cancer, and those diagnosed with lung cancer or their family members/carers are taken into account when planning and delivering this study.
What would PPI advisory group members be expected to do?
PPI Group members will be asked to attend up to 3 workshops, review documents being designed for study participants, join a study steering committee and help share the final study results. You can choose to take part in all or some of these activities.
Timeline/tenure
The first workshop is expected to be held in June/July 2023 during the preparation of the final funding application to the National Institute for Health and Care Research (NIHR).
If funded, the study will start early 2024 and there will be an opportunity to continue participation in the PPI advisory group at that point.
Remuneration
You will receive payment for any time spent in these activities and travel expenses for any face to face meetings, although most of the work will be completed remotely.
If you are interested and would like more information please contact dart@oncology.ox.ac.uk
CanPredict: Lung cancer risk prediction
A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, able to identify the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.
The ‘CanPredict’ tool has used anonymised health records of over 19 million adults from across the UK, and has the potential substantially to reduce the burden on NHS staff, saving time, money and streamlining the administrative process for better patient experience.
DART researcher, Dr Weiqi Liao, lead author on the publication and a data scientist in the Nuffield Department of Primary Care Health Sciences, University of Oxford, said: ‘Our tool, CanPredict, works by examining existing patient health records, so it could be run on a per GP surgery basis or nationally, automatically and objectively prioritising patients and alerting their GPs that they might benefit from further screening.
‘Because of this, CanPredict has the potential to substantially reduce the burden on NHS staff, saving time, money and streamlining the administrative process for better patient experience.’
Read the full University of Oxford press release here and the article here.
National lung cancer screening
The UK National Screening Committee has today recommended the introduction of targeted lung cancer screening.
Targeted screening for lung cancer is recommended for people aged 55 to 74 identified as being at high risk of lung cancer. Evidence shows that screening with low-dose computed tomography:
reduces lung cancer mortality
is acceptable to patients and professionals if adequately resourced and quality assured
DART has been working with NHSE sites which have piloted Targeted Lung Health Checks. Their success has led to this extension of the programme to all the four UK nations. As one example, the Doncaster programme has been operational since mid-March 2021 and in the first year 11,857 lung health check calls and more than 5,000 initial scans have taken place; 50 previously unknown lung cancers have been found, 73% of which were early-stage lung cancers. Seven other cancers have also been confirmed and 41 patients (75%) have been given life-saving cancer treatment so far.
DART will be working with lung health check sites to collect and use data to develop artificial intelligence methods to further improve early detection and thus lead to earlier and more successful treatment.
Read the UK NSC announcement here and the response from the Roy Castle Lung Cancer Foundation here.
Portsmouth encourages participation in Lung Health Checks
People over 55 but younger than 75 who have ever smoked are being offered a free lung health check. See a video here or read NHS news items here and here.
This is part of an expanding lung cancer screening programme.
Celebrate Doncaster LHC’s success
The Doncaster programme has been operational since mid-March 2021 and in the first year 11,857 lung health check calls and more than 5,000 initial scans have taken place; 50 lung cancers have been found, 73% of which were early-stage lung cancers. Seven other cancers have also been confirmed and 41 patients (75%) have been given life-saving cancer treatment so far.
Read more about this pioneering lung screening trial that is saving lives in Doncaster here
Approvals and adoption
NIHR
DART is very pleased that the project has been adopted onto the NIHR portfolio and is therefore deemed eligible for NIHR Clinical Research Network support. Further information about CRN support can be found on the NIHR website.
The 15 Local Clinical Research Networks (LCRN) cover the length and breadth of England and are available to coordinate and support the delivery of research across the NHS in England.
Health Research Authority HRA
DART has had confirmation that HRA and Health and Care Research Wales (HCRW) Approval has been given for the study, on the basis described in the application form, protocol, supporting documentation and clarifications requested and received.
DART has also had notification of Confidentiality Advisory Group (CAG) conditional support, as per the excerpt from their letter below.
“The role of the Confidentiality Advisory Group (CAG) is to review applications submitted under these Regulations and to provide advice to the Health Research Authority on whether application activity should be supported, and if so, any relevant conditions. This application was considered at the CAG meeting held on 10 February 2022.
Health Research Authority decision
The Health Research Authority, having considered the advice from the Confidentiality Advisory Group as set out below, has determined the following:
The application, to allow the disclosure of confidential patient information from participating trusts to the Oxford University Hospitals NHS Foundation Trust, is conditionally supported, subject to compliance with the standard and specific conditions of support.
Please note that the legal basis to allow access to the specified confidential patient information without consent is now in effect.”
The conditions of support allow for the project to proceed as planned and will be addressed by mid-May 2022. DART will comply with the HRA annual review.
CAG reference: 22/CAG/0010
IRAS project ID: 301420
REC reference: 21/WM/0278
NCIMI: Seven Strategies for Success – for adoption and deployment of Artificial Intelligence in Medical Diagnostics
NCIMI, working with The Behavioural Architects have created a guide to support their ambition of driving greater adoption of AI within the healthcare system, through the application of behavioural science.
